ADVA
ADVA (FSE: ADV) today announced that it’s enabling service provider customers to offer GPS/GNSS-backup-as-a-service (GBaaS). A wide range of industries are increasingly reliant on satellite-delivered timing, but with threats including jamming and spoofing cyberattacks on the rise, operators need to find ways to safeguard services that rely on positioning, navigation, and timing (PNT) information. In-network timing based on NTP and PTP is also increasingly vulnerable to cyber threats. As a response, ADVA is now empowering service providers to offer GBaaS and enable end users to address new guidelines and standards for redundant PNT architectures. GBaaS meets the latest recommendations for PNT homeland security like US Executive Order 13905. Leveraging ADVA’s aPNT+™ technology , it eliminates the risks and costs associated with GNSS dependence.
“Threats to hamper PNT capabilities are growing, and much of the world’s critical infrastructure is still without adequate protection from GNSS vulnerabilities. All of that can change when service providers are able to offer GBaaS. It’s based on our aPNT+™ platform, which leverages a suite of technologies, including multi-band GNSS receivers and AI- and ML-based management software. As well as making networks more resilient against cyberattacks, our aPNT+™ platform also delivers highly accurate backup when GNSS fails,” said Gil Biran, GM of Oscilloquartz, ADVA. “Now service providers can offer ADVA’s aPNT+™ protection as a subscription-based service as part of their SLAs. This will enable many more timing networks to achieve very high levels of resilience and assurance. Across a wide range of industries, this will be the easiest and most flexible way to guarantee robust PNT services.”
ADVA’s GBaaS solution employs a combination of multi-layer detection, multi-source backup and fault-tolerant mitigation to render timing networks more secure. Embedded in all timing devices, ADVA’s Syncjack™ technology provides comprehensive and precise synchronization performance monitoring and analytics, enabling the Ensemble Sync Director network management suite to intelligently operate and prioritize multi-source timing feeds across the network. Onboard multi-band GNSS receivers boost timing accuracy and also protect against attacks like jamming and spoofing. But for those times when GNSS is either unavailable or compromised, a dispersed network of autonomous cesium atomic clocks and network backup timing feeds is always sitting on standby, ready to deliver highly accurate network timing over long periods of GNSS unavailability.
“GBaaS is a completely new way for service providers to sell critical PNT infrastructure as a service without the burden of investment and maintenance. For the first time, they can offer their customers SLAs at a range of levels that ensure the resilient and assured timing needed across time-sensitive networks and applications,” commented Nino De Falcis, senior director of business development at Oscilloquartz, ADVA. “The flexibility and protection that GBaaS affords is bad news for any malicious actors looking to attack PNT services. Service providers can now offer their customers a guarantee: When GNSS is compromised or goes offline, ADVA’s robust network of defense-in-depth PTP timing devices will be there to provide the accuracy and backup they urgently need.”
Further information on ADVA’s GBaaS solution is available in these slides: https://adva.li/gbaas-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005526/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
